| T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas SM Pollack, Q He, JH Yearley, R Emerson, M Vignali, Y Zhang, ... Cancer 123 (17), 3291-3304, 2017 | 241 | 2017 |
| Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer YD Seo, X Jiang, KM Sullivan, FG Jalikis, KS Smythe, A Abbasi, M Vignali, ... Clinical Cancer Research 25 (13), 3934-3945, 2019 | 175 | 2019 |
| Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology M von Mehren, JM Kane, M Agulnik, MM Bui, J Carr-Ascher, E Choy, ... Journal of the National Comprehensive Cancer Network 20 (7), 815-833, 2022 | 147 | 2022 |
| Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment KC Shibuya, VK Goel, W Xiong, JG Sham, SM Pollack, AM Leahy, ... PloS one 9 (5), e96565, 2014 | 138 | 2014 |
| NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma SM Pollack, AA Jungbluth, BL Hoch, EA Farrar, M Bleakley, DJ Schneider, ... Cancer 118 (18), 4564-4570, 2012 | 138 | 2012 |
| Novel therapeutic approaches in chondrosarcoma G Polychronidou, V Karavasilis, SM Pollack, PH Huang, A Lee, RL Jones Future Oncology 13 (7), 637-648, 2017 | 123 | 2017 |
| Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial S Zhang, K Kohli, RG Black, L Yao, SM Spadinger, Q He, VG Pillarisetty, ... Cancer immunology research 7 (8), 1237-1243, 2019 | 109 | 2019 |
| Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone E Palmerini, RL Jones, E Marchesi, A Paioli, M Cesari, A Longhi, ... BMC cancer 16, 1-8, 2016 | 97 | 2016 |
| Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial SM Pollack, MW Redman, KK Baker, MJ Wagner, BA Schroeder, ... JAMA oncology 6 (11), 1778-1782, 2020 | 93 | 2020 |
| Emerging targeted and immune-based therapies in sarcoma SM Pollack, M Ingham, MB Spraker, GK Schwartz Journal of Clinical Oncology 36 (2), 125-135, 2018 | 84 | 2018 |
| NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine SM Pollack, Y Li, MJ Blaisdell, EA Farrar, J Chou, BL Hoch, ET Loggers, ... PloS one 7 (2), e32165, 2012 | 84 | 2012 |
| A contemporary large single-institution evaluation of resected retroperitoneal sarcoma PJ Bremjit, RL Jones, X Chai, G Kane, ET Rodler, ET Loggers, SM Pollack, ... Annals of surgical oncology 21, 2150-2158, 2014 | 82 | 2014 |
| First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1 N Somaiah, MS Block, JW Kim, GI Shapiro, KT Do, P Hwu, JP Eder, ... Clinical Cancer Research 25 (19), 5808-5817, 2019 | 79 | 2019 |
| Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells SM Pollack, RL Jones, EA Farrar, IP Lai, SM Lee, J Cao, VG Pillarisetty, ... Journal for immunotherapy of cancer 2, 1-10, 2014 | 78 | 2014 |
| More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments D Katz, E Palmerini, SM Pollack American Society of Clinical Oncology Educational Book 38, 925-938, 2018 | 75 | 2018 |
| MRI radiomic features are independently associated with overall survival in soft tissue sarcoma MB Spraker, LS Wootton, DS Hippe, KC Ball, JC Peeken, MW Macomber, ... Advances in radiation oncology 4 (2), 413-421, 2019 | 65 | 2019 |
| First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma … SM Pollack, H Lu, S Gnjatic, N Somaiah, RB O’Malley, RL Jones, FJ Hsu, ... Journal of immunotherapy 40 (8), 302-306, 2017 | 63 | 2017 |
| The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients SM Pollack Expert review of vaccines 17 (2), 107-114, 2018 | 59 | 2018 |
| Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants AJ Bathan, A Constantinidou, SM Pollack, RL Jones Current opinion in oncology 25 (4), 384-389, 2013 | 55 | 2013 |
| Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics G Jour, JD Scarborough, RL Jones, E Loggers, SM Pollack, CC Pritchard, ... Human pathology 45 (8), 1563-1571, 2014 | 54 | 2014 |
Robin JonesROYAL MARSDEN AND INSTITUE OF CANCER RESEARCH在 doctors.org.uk 的电子邮件经过验证
